AU1618000A - Use of radioligands to screen inhibitors of amyloid-beta peptide production - Google Patents

Use of radioligands to screen inhibitors of amyloid-beta peptide production

Info

Publication number
AU1618000A
AU1618000A AU16180/00A AU1618000A AU1618000A AU 1618000 A AU1618000 A AU 1618000A AU 16180/00 A AU16180/00 A AU 16180/00A AU 1618000 A AU1618000 A AU 1618000A AU 1618000 A AU1618000 A AU 1618000A
Authority
AU
Australia
Prior art keywords
inhibitors
amyloid
beta
radioligands
beta peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16180/00A
Other languages
English (en)
Inventor
Richard E. Olson
Dietmar A. Seiffert
Lorin Andrew Thompson
Robert C. Zaczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU1618000A publication Critical patent/AU1618000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
AU16180/00A 1998-11-12 1999-11-12 Use of radioligands to screen inhibitors of amyloid-beta peptide production Abandoned AU1618000A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10814798P 1998-11-12 1998-11-12
US60108147 1998-11-12
US13128499P 1999-04-27 1999-04-27
US60131284 1999-04-27
PCT/US1999/026715 WO2000028331A1 (en) 1998-11-12 1999-11-12 Use of radioligands to screen inhibitors of amyloid-beta peptide production

Publications (1)

Publication Number Publication Date
AU1618000A true AU1618000A (en) 2000-05-29

Family

ID=26805566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16180/00A Abandoned AU1618000A (en) 1998-11-12 1999-11-12 Use of radioligands to screen inhibitors of amyloid-beta peptide production

Country Status (8)

Country Link
US (1) US6331408B1 (US06331408-20011218-C00079.png)
EP (1) EP1129355B1 (US06331408-20011218-C00079.png)
AT (1) ATE300052T1 (US06331408-20011218-C00079.png)
AU (1) AU1618000A (US06331408-20011218-C00079.png)
CA (1) CA2346099A1 (US06331408-20011218-C00079.png)
DE (1) DE69926254D1 (US06331408-20011218-C00079.png)
NO (1) NO20011891L (US06331408-20011218-C00079.png)
WO (1) WO2000028331A1 (US06331408-20011218-C00079.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346099A1 (en) * 1998-11-12 2000-05-18 Dupont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
US6737038B1 (en) * 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
JP4615727B2 (ja) 1998-12-24 2011-01-19 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質生成の阻害剤としてのスクシノイルアミノベンゾジアゼピン
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
JP2004508289A (ja) 2000-04-03 2004-03-18 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生の阻害剤としての環状ラクタム
AU2001261728A1 (en) * 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
IL147629A0 (en) * 2000-06-01 2002-08-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
DK1379634T3 (en) * 2001-04-20 2018-03-19 The Univ Of Georgia Research Foundation Inc ACTIVE LOCATION INACTIVATORS
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
JP2015529251A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎｏｔｃｈ阻害剤としての三環系複素環式化合物
CN104854097A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物
WO2014047374A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5538845A (en) * 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
EP0763537A3 (en) * 1993-05-14 1997-10-22 Genentech Inc Non-peptides farnesyl transfer inhibitors
IL110525A0 (en) * 1993-08-09 1994-11-11 Lilly Co Eli Identification and use of protease inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
CA2346099A1 (en) * 1998-11-12 2000-05-18 Dupont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production

Also Published As

Publication number Publication date
EP1129355A1 (en) 2001-09-05
CA2346099A1 (en) 2000-05-18
NO20011891L (no) 2001-07-02
ATE300052T1 (de) 2005-08-15
WO2000028331A1 (en) 2000-05-18
NO20011891D0 (no) 2001-04-17
DE69926254D1 (de) 2005-08-25
EP1129355B1 (en) 2005-07-20
US6331408B1 (en) 2001-12-18

Similar Documents

Publication Publication Date Title
AU1618000A (en) Use of radioligands to screen inhibitors of amyloid-beta peptide production
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
WO2001087354A3 (en) Use of small molecule radioligands for diagnostic imaging
WO2003042654A3 (en) Multi-parameter high throughput screening assays (mphts)
MXPA04001940A (es) Tratamiento para desordenes del sistema nervioso central.
MY131442A (en) Excitatory amino acid receptor antagonists
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
WO2003039467A3 (en) Monoclonal antibodies specific for beta-amyloid.
BG106249A (en) Composition of a-beta peptide and process for producing same
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders
MX9707636A (es) Ascomicinas.
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR FIXING TAU AND MAP2c PROTEINS
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
WO2004005882A3 (en) Multi-parameter high throughput screening assays (mphts)
WO2004035606A3 (en) Bace binding peptides and uses thereof
WO1999006838A3 (en) Novel method of detecting amyloid-like fibrils or protein aggregates
CA2302629A1 (en) Estrogen receptor
WO2003045325A3 (en) Dopaminergic stimulatory factor
WO2004063222A3 (en) Novel preadipocyte factor-1-like polypeptides
WO2001029266A3 (en) Identification of arsacs mutations and methods of use therefor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase